ExeVir Closes US$50M Series A Financing
ExeVir, a Ghent, Belgium-based company developing single domain antibody therapies providing broad protection against viral infections, closed its Series A financing raising a total of US$50m. The financing, announced in March 2021, was led by Fund+ with participation from VIB, UCB Ventures, SFPI-FPIM, V-Bio Ventures and new investors SRIW, Noshaq, Vives IUF, SambrInvest, as well as several Belgian family offices. In conjunction with the funding, Caroline Thielen, Investment Manager at SRIW will join the Board of ExeVir Bio alongside Torsten Mummenbrauer, CEO of ExeVir Bio, Philippe Monte...
Source: finsmes.com